Piero Crespo obtained his BSc degree in Biology from Universidad Autónoma de Madrid (1986) and his Ph.D degree in Biochemistry and Molecular Biology from Universidad de Cantabria in 1991. Always interested in signal transduction, in 1992 he moved to the United States as a Fulbright scholar, to join Silvio Gutkind's laboratory at the National Institutes of Health (Bethesda, MD). During his stay at NIH from 1992 to 1996, his main achievements were the unravelling of the role of beta-gamma dimers in the activation of the RAS-ERK pathway by G protein-coupled receptors and the identification of VAV as an exchange factor for RHO GTPases, both published in Nature as first author. He returned to Spain in 1996 with a "Contrato de Reincorporación" and gained tenure at the Spanish Research Council (CSIC) as a Staff Scientist in 1998, establishing his group at the Instituto de Investigaciones Biomédicas (IIB), in Madrid. In 2008 he was promoted to Full Professor. In 2007 his group was selected as one of the ten groups that constituted the embryo of the Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC) and moved to Santander. Currently, he is the director of the institute. Prof. Crespo's research has been always focused on the regulation of the RAS-ERK pathway, in particular on how subcellular localization and signal compartmentalization affect the biochemical and biological outputs of this signalling route, both in physiological and pathological contexts, in particular in cancer, and how space-regulated effects can be exploited as antineoplastic strategies. Prof. Crespo has authored three patents and 110 peer-reviewed publications in SCI journals, including: Nature, Science, Cancer Cell, Molecular Cell, Nature Cell Biology, Nature Communications, EMBO J., J Cell. Biol, among 61 publications as first or principal author. Throughout his career he has been regularly funded by national and international grants, including two EU FP6 grants; AICR; and AECC projects. His group is included in CIBERONC. He has mentored 18 doctoral theses, two of which earned the University of Cantabria Doctorate Award. He has been honored by six national and international research awards. He serves in five editorial boards and acts as a reviewer for numerous scientific journals and granting agencies. He has been invited as a speaker in more than 100 meetings, workshops and seminar series at numerous national and foreign universities and scientific institutions. He is an Honorary Professor at Universidad Autónoma de Madrid and at Universidad de Cantabria.
Spatial Regulation of Ras-ERK Signals in Cancer
Research lines
-
Spatial regulation of Ras-ERK signals in physiological processes and in cancer
-
Development of antitumoral drugs targeting protein-protein interactions in the Ras-ERK pathway
Funding
-
“Nuevas dianas moleculares en la ruta Ras-ERK: potencial terapéutico en el cáncer de tiroides”. Asociación Española Contra el Cáncer (AECC). GCB141423113. Proyecto coordinado 2014-2019.
-
Red Temática de Investigación Cooperativa sobre el Cáncer (RTICC). RD/12/0036/0033. 2012-2015.
-
“Proteínas Scaffold como moduladores de la resistencia a inhibidores de la ruta RAS-ERK en melanoma”. SAF-2015 63638R. 2016-2018.
-
Grupo incluido en: Centro de Investigación Biomédica en Red sobre el Cáncer (CIBERONC). (CB16/12/00436). 2017-2023.
-
“ERK spatial distribution and dimerization: implications in carcinogenesis”. RTI2018-096658B. 2019-2021.
-
“Repurposing MAPK inhibitors for the treatment of COVID-19”. Proyecto intramural CSIC. CSIC-COV19-095. 2020.
-
Grupo incluido en la Plataforma PTI SALUD GLOBAL-CSIC: SG2103031_2107300020.
-
“Reutilización de inhibidores de MAPK para el tratamiento de COVID-19”. G.CANTABRIA: 2020UIC22-PUB0008.
-
“Proteínas HOX como mediadores de la ruta RAS-ERK”. PID2021-126288OB-I00. 2022-2025. 294.000€. Investigador Principal.
-
“Desarrollo de un marcador de la respuesta terapéutica del melanoma BRAF positivo”. Proyectos de Prueba de Concepto PDC2022-133569-I00. 2023-2025.